5-Triethylsilyl-3-furaldehyde | 130493-22-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-Triethylsilyl-3-furaldehyde
• 英文别名: 2-Triethylsilyl-4-furaldehyde；3-Furancarboxaldehyde, 5-(triethylsilyl)-；5-triethylsilylfuran-3-carbaldehyde
• CAS: 130493-22-0
• 化学式: C₁₁H₁₈O₂Si
• 分子量: 210.348
• InChiKey: LXHUUMYZAWTHIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.81
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-Triethylsilyl-3-furaldehyde 在 四(三苯基膦)钯 氧气 、 rose bengal 、 二异丁基氢化铝 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 二氯甲烷 为溶剂， -80.0~60.0 ℃ 、202.65 kPa 条件下， 反应 24.0h， 生成 5-Hydroxy-4-{6-hydroxy-5-[(E)-4-methyl-6-(2,6,6-trimethyl-cyclohex-1-enyl)-hex-3-enyl]-3,6-dihydro-2H-pyran-2-yl}-5H-furan-2-one
  参考文献：
  名称：

  Synthesis of manoalide using a 1,2-metallate rearrangement

  摘要：

  马诺酰胺是一种海洋抗炎酯类化合物，它是通过高阶铜酸盐的 1,2-金属棓酸盐重排和钯催化碘代烯的羰基化反应生成二氢吡喃酮中心环而合成的。

  DOI：

  10.1039/a701936j
• 作为产物：
  描述：

  3-糠醛 、 三乙基氯硅烷 在 lithium morpholide 、 仲丁基锂 作用下， 以 四氢呋喃 为溶剂， 以73%的产率得到5-Triethylsilyl-3-furaldehyde
  参考文献：
  名称：

  经由铜（I）介导的1，2-金属盐重排合成（+）-甘醇内酯。

  摘要：

  对映体合成的磷脂酶A（2）抑制剂（+）-（4R）-马来酰内酯，其中酯类萜骨架的所有25个碳原子均由3-呋喃醛，三甲基铝烷，环氧乙烷，CO，β-紫罗兰酮和炔丙基构成溴化物。最长的线性序列（12个步骤）的总产率为12％。关键步骤包括（a）锆催化的碳铝化反应以构建C10-C11三取代的烯烃，（b）Cu（I）介导的1,2-金属盐重排以构建C6-C7三取代的烯烃，（c）a锐利的动力学拆分，可确保（4R）-立体化学，（d）通过Mo催化的高炔丙醇的环异构化反应生成5-stannyl-2,3-dihydrofuran，以及（e）通过光氧化α-羟基呋喃酮环来构建羟基呋喃酮环甲硅烷基呋喃。

  DOI：

  10.1021/jo0268097

文献信息

• Intermediates and processes for preparing 4-substituted 2-5(H)-furanones
  申请人：Allergan, Inc.

  公开号：US05082954A1

  公开（公告）日：1992-01-21

  Anti-inflammatory 4-substituted 2-furanones are made from intermediates having the formulas: ##STR1## in which R.sub.1, R.sub.2 and R.sub.3 independently are n-alkyl of 1 to 6 carbons, or branched chain alkyl of 1 to 6 carbons; X is H, OH, NH.sub.2, I or Br; R.sub.4 is H, alkyl of 1-20 carbons, phenyl[C.sub.1 -C.sub.20 alkyl], naphthyl[C.sub.1 -C.sub.20 alkyl], CH.sub.2 OH, CH.sub.2 NH.sub.2, CH.sub.2 CH.sub.2 OH, CH.sub.2 --CHO, CH.sub.2 --COOH or CH.sub.2 --COOR.sub.5, and R.sub.5 is alkyl of 1 to 6 carbons, with the proviso that when X is hydrogen then R.sub.4 is selected from the group consisting of CH.sub.2 OH, CH.sub.2 NH.sub.2, CH.sub.2 CH.sub.2 OH, CH.sub.2 --CHO, or CH.sub.2 --COOR.sub.5 ; ##STR2## in which R.sub.1, R.sub.2 and R.sub.3 independently are n-alkyl of 1 to 6 carbons, or branched chain alkyl or 1 to 6 carbons, and R.sub.5 is alkyl or 1 to 6 carbons; ##STR3## in which R.sub.1, R.sub.2 and R.sub.3 independently are n-alkyl of 1 to 6 carbons, or branched chain alkyl of 1 to 6 carbons, and R.sub.6 is phenyl, or alkyl of 1 to 6 carbons, and ##STR4## in which R.sub.1, R.sub.2 and R.sub.3 independently are n-alkyl of 1 to 6 carbons, or branched chain alkyl of 1 to 6 carbons.

  抗炎症的4-取代的2-呋喃酮是由具有以下结构的中间体制备的：##STR1## 其中R.sub.1，R.sub.2和R.sub.3独立地是1到6个碳原子的n-烷基，或者1到6个碳原子的支链烷基；X是H，OH，NH.sub.2，I或Br；R.sub.4是H，1-20个碳原子的烷基，苯基[C.sub.1-C.sub.20烷基]，萘基[C.sub.1-C.sub.20烷基]，CH.sub.2 OH，CH.sub.2 NH.sub.2，CH.sub.2 CH.sub.2 OH，CH.sub.2 --CHO，CH.sub.2 --COOH或CH.sub.2 --COOR.sub.5，而R.sub.5是1到6个碳原子的烷基，但当X为氢时，R.sub.4从CH.sub.2 OH，CH.sub.2 NH.sub.2，CH.sub.2 CH.sub.2 OH，CH.sub.2 --CHO或CH.sub.2 --COOR.sub.5的组中选择；##STR2## 其中R.sub.1，R.sub.2和R.sub.3独立地是1到6个碳原子的n-烷基，或者1到6个碳原子的支链烷基，而R.sub.5是1到6个碳原子的烷基；##STR3## 其中R.sub.1，R.sub.2和R.sub.3独立地是1到6个碳原子的n-烷基，或者1到6个碳原子的支链烷基，而R.sub.6是苯基，或者1到6个碳原子的烷基，以及##STR4## 其中R.sub.1，R.sub.2和R.sub.3独立地是1到6个碳原子的n-烷基，或者1到6个碳原子的支链烷基。
• Anti-inflammatory furanones
  申请人：Allergan, Inc.

  公开号：US05134128A1

  公开（公告）日：1992-07-28

  New 5-hydroxy-2-furanone compounds having anti-inflammatory, immunosuppressive and anti-proliferative activity and are useful in treating psoriasis and modifying calcium homeostasis.

  新的具有抗炎、免疫抑制和抗增殖活性的5-羟基-2-呋喃酮化合物对治疗牛皮癣和调节钙稳态具有用处。
• Pharmaceutical compositions and method for administering 3 and
  申请人：Allergan, Inc.

  公开号：US05268387A1

  公开（公告）日：1993-12-07

  3 and 4-substituted 2(5H)-furanone compounds influence the balance between bone production and bone resorption in mammals, including humans. The active compounds are administered to mammals, including humans, in an effective dose which ranges between 0.05 to 100 mg per kilogram, body weight, per day, for the purpose of influencing the balance between bone production and bone resorption, and particularly for treating osteoporosis.

  3和4-取代的2(5H)-呋喃酮化合物影响哺乳动物，包括人类的骨生成和骨吸收之间的平衡。这些活性化合物以有效剂量（每公斤体重范围在0.05至100毫克之间）被用于哺乳动物，包括人类，旨在影响骨生成和骨吸收之间的平衡，特别用于治疗骨质疏松症。
• 4-ethyl and 4-ethenyl-5-hydroxy-2(5H)-furanones substituted on alpha
  申请人：Allergan, Inc.

  公开号：US05013850A1

  公开（公告）日：1991-05-07

  Compounds of Formula 1, and of Formula 2, ##STR1## in which R.sub.1 is H or alkyl of 1 to 20 carbon, CO--R.sub.1 * CO--O--R.sub.1 * CO--NH--R.sub.1 * or PO(OR.sub.1 *).sub.2 or PO(OR.sub.1 *)R.sub.1 * where R.sub.1 * independently is alkyl of 1 to 20 carbons, phenyl, or substituted phenyl; X is long chain alkyl having at least 5 carbon atoms, long chain alkyl of at least 5 carbons substituted with an aryl group, or long chain alkyl of at least 5 carbons substituted with a substituted aryl group; Y is COOH, COOR.sub.2, CONH.sub.2, CONHR.sub.2, CON(R.sub.2).sub.2, CHO, COR.sub.2 ; COCF.sub.3, COCHF.sub.2, CH.dbd.NR.sub.2, CR.sub.2 .dbd.N--R.sub.2, CH.dbd.N--NHR.sub.2, CH.dbd.N--N(R.sub.2).sub.2, CH.dbd.NOH, CR.sub.2 .dbd.N--OH, CH.dbd.NOR.sub.2, CR.sub.2 .dbd.NOR.sub.2, CH.sub.2 OH, CHR.sub.2 OH, C(R.sub.2).sub.2 OH, CH.sub.2 OR.sub.2 * CHR.sub.2 OR.sub.2 * C(R.sub.2).sub.2 OR.sub.2 * SO.sub.2 R.sub.2, PO(OR.sub.3).sub.2, and PS(OR.sub.3).sub.2, where R.sub.2 independently is alkyl, phenyl, or substituted phenyl, R.sub.2 * is alkyl, phenyl, substituted phenyl, alkanoyl, or aroyl, and R.sub.3 is H, alkyl, phenyl or substituted phenyl; W is H, alkyl, phenyl, COOH, COOR.sub.4, CONHR.sub.4, CON(R.sub.4).sub.2, and Z is H or alkyl, are disclosed. The compounds possess anti-inflammatory activity.

  化合物的化学式1和化学式2如下：##STR1## 其中R.sub.1为H或含有1至20个碳原子的烷基，CO--R.sub.1 * CO--O--R.sub.1 * CO--NH--R.sub.1 *或PO(OR.sub.1 *).sub.2或PO(OR.sub.1 *)R.sub.1 *，其中R.sub.1 *独立地为含有1至20个碳原子的烷基、苯基或取代苯基；X为至少含有5个碳原子的长链烷基、至少含有5个碳原子的长链烷基取代的芳基、或至少含有5个碳原子的长链烷基取代的取代芳基；Y为COOH、COOR.sub.2、CONH.sub.2、CONHR.sub.2、CON(R.sub.2).sub.2、CHO、COR.sub.2、COCF.sub.3、COCHF.sub.2、CH.dbd.NR.sub.2、CR.sub.2.dbd.N--R.sub.2、CH.dbd.N--NHR.sub.2、CH.dbd.N--N(R.sub.2).sub.2、CH.dbd.NOH、CR.sub.2.dbd.N--OH、CH.dbd.NOR.sub.2、CR.sub.2.dbd.NOR.sub.2、CH.sub.2OH、CHR.sub.2OH、C(R.sub.2).sub.2OH、CH.sub.2OR.sub.2*CHR.sub.2OR.sub.2*C(R.sub.2).sub.2OR.sub.2*SO.sub.2R.sub.2、PO(OR.sub.3).sub.2和PS(OR.sub.3).sub.2，其中R.sub.2独立地为烷基、苯基或取代苯基，R.sub.2 *为烷基、苯基、取代苯基、烷酰基或芳酰基，R.sub.3为H、烷基、苯基或取代苯基；W为H、烷基、苯基、COOH、COOR.sub.4、CONHR.sub.4、CON(R.sub.4).sub.2；Z为H或烷基。这些化合物具有抗炎活性。
• Di-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega alkanedioates
  申请人：Allergan, Inc.

  公开号：US05169963A1

  公开（公告）日：1992-12-08

  Compounds of the formula ##STR1## in which R.sub.1 independently is H or alkyl of 1 to 29 carbons, CO-R.sub.2, CO-O-R.sub.2, CO-NH-R.sub.2, or PO(OR.sub.2).sub.2 or PO(OR.sub.2)R.sub.2, where R.sub.2 independently is H, alkyl of 1 to 20 carbons, phenyl, or lower alkyl substituted phenyl or halogen substituted phenyl; A is (CH.sub.2).sub.n where n ranges between 0 to 30, or A is a a divalent branch chained alkyl radical, or cycloalkyl radical, having a total of 3 to 30 carbons; R.sub.3 independently is an alkyl group having 4 to 20 carbons, and X is O or NH, have anti-inflammatory activity.

  具有以下结构式的化合物 ##STR1## 中，其中 R.sub.1 独立地为 H 或含有 1 到 29 个碳原子的烷基，CO-R.sub.2，CO-O-R.sub.2，CO-NH-R.sub.2，或 PO(OR.sub.2).sub.2 或 PO(OR.sub.2)R.sub.2，其中 R.sub.2 独立地为 H，含有 1 到 20 个碳原子的烷基，苯基，或取代苯基的较低烷基或卤代苯基；A 为 (CH.sub.2).sub.n，其中 n 范围在 0 到 30 之间，或 A 为二价支链烷基基团，或环烷基基团，总共含有 3 到 30 个碳原子；R.sub.3 独立地为含有 4 到 20 个碳原子的烷基基团，X 为 O 或 NH，具有抗炎活性。